A prequalification pilot designed to assess biosimilar versions of Roche’s Rituxan and Herceptin has attracted global interest from manufacturers, says WHO executive.
Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.
Ncardia and Horizon Discovery have partnered to provide custom, genetically-modified and differentiated human cells for drug discovery and preclinical models.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
Within days of Samsung Bioepis sending its Soliris candidate to the clinic, the firm details its development process, novel biologics ambitions, and plans to become ‘the single dominant player in biosimilars’.
Sarepta Therapeutics signed a long-term, strategic manufacturing partnership with Paragon Bioservices to produce micro-dystrophin to grow its gene therapy program.
